Your search for baricitinib returned 4 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Lea Eslava-Kim, PharmD remove

Your search for baricitinib returned 4 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Study: Baricitinib Superior to Conventional DMARD

Eli Lilly and Incyte announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib for the treatment of patients with moderately-to-severely active rheumatoid arthritis (RA).
Drugs in the Pipeline

FDA to Review Once-Daily Oral RA Tx

Eli Lilly and Incyte announced that the New Drug Application (NDA) for once-daily oral baricitinib has been submitted to the Food and Drug Administration (FDA) for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Drugs in the Pipeline

Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs

Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.